Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab and Lenvatinib for Conversion Therapy in Unresectable HCC
NCT06215651Phase 2Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Mar 2024
- Primary completion
- Jan 2025
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab in hepatocellular carcinoma (HCC), sponsored by Peking Union Medical College Hospital. Started Mar 2024; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06215651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06215651.